Related Experiment Video
Updated: Dec 15, 2025
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
538
Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
Miao Miao1,2, Yuhui Li1,2, Bo Huang1,2
1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.
Dermatology and Therapy
|July 11, 2020
Summary
Hypomyopathic dermatomyositis (DM), a condition with skin issues but no muscle weakness, can be challenging to treat. Low-dose interleukin-2 (IL-2) offers a safe and effective therapeutic option for this specific DM subtype.
Area of Science:
- Dermatology
- Rheumatology
- Immunology
Background:
- Hypomyopathic dermatomyositis (DM) is characterized by skin lesions without significant muscle weakness.
- Cutaneous manifestations in hypomyopathic DM can be treatment-resistant.
- Standard therapies may be less effective for the skin symptoms of hypomyopathic DM.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose interleukin-2 (IL-2) in a patient with hypomyopathic DM.
- To explore novel treatment strategies for refractory cutaneous dermatomyositis.
Main Methods:
- Case report of a 61-year-old patient with hypomyopathic DM.
- Patient had failed to respond to conventional therapies.
- Treatment administered was low-dose interleukin-2 (IL-2).
Main Results:
- The patient with hypomyopathic DM showed a successful response to low-dose IL-2.
- Treatment with low-dose IL-2 resulted in no significant adverse side effects.
- This suggests a favorable safety profile for IL-2 in this context.
Conclusions:
- Low-dose interleukin-2 (IL-2) is a safe and effective treatment for hypomyopathic dermatomyositis.
- IL-2 represents a promising therapeutic avenue for refractory cutaneous manifestations of DM.
- Further research into IL-2 for autoimmune skin conditions is warranted.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
370
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
370
01:24T Cell Types and Functions
1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K